Fosbretabulin: Phase II/III started

Mateon began the double-blind, placebo-controlled, U.S. Phase II/III FOCUS trial to evaluate 60 mg/m 2 CA4P on days 1 and 15 of a 28-day cycle plus physician’s choice of chemotherapy plus Avastin bev...